Anti–PD-1 therapies may emerge as first-line SoC for R/M NPC
08 Jul 2021
byChristina Lau
Adding the anti–PD-1 monoclonal antibodies toripalimab or camrelizumab to first-line standard of care (SoC) with gemcitabine and cisplatin (GC) significantly improves progression-free survival (PFS) vs GC alone in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC), two phase III trials have shown. These results, reported at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021), may position toripalimab or camrelizumab in combination with GC as a new first-line SoC in this patient population.
